Which meeting type is defined as any meeting other than Type A or Type B?

The correct answer is Type C Meeting. In the context of regulatory meetings with the FDA, meetings are classified into different types based on their purpose and significance.

Type A meetings are typically held to address critical issues that could delay the development of a drug, such as a clinical hold or issues related to the design of a pivotal study. Type B meetings are standard meetings that occur at key development milestones, usually regarding important aspects of the drug development process, like pre-IND discussions or End-of-Phase meetings.

Type C meetings encompass all other meetings that do not fall into the Type A or Type B categories. This includes meetings that may address less critical issues or seek advice on various topics that do not directly lead to regulatory decision-making. Therefore, since Type C meetings are defined as those that are neither Type A nor Type B, it correctly captures the essence of the question asked.

Understanding the classifications can help professionals effectively navigate communications with the FDA, ensuring they select the appropriate meeting type for their specific circumstances.